Hostname: page-component-cd9895bd7-q99xh Total loading time: 0 Render date: 2024-12-31T14:47:25.417Z Has data issue: false hasContentIssue false
  • English
  • Français

Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses

Published online by Cambridge University Press:  03 January 2018

Pierre V. Tran ,
Mary Anne Dellva ,
Gary D. Tollefson ,
Anita L. Wentley  and
Charles M. Beasley Jr
Pierre V. Tran*
Affiliation:
Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana, USA
Mary Anne Dellva
Affiliation:
Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana, USA
Gary D. Tollefson
Affiliation:
Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana, USA
Anita L. Wentley
Affiliation:
Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana, USA
Charles M. Beasley Jr
Affiliation:
Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana, USA
*
Dr Pierre V. Tran, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 0538, Indianapolis, IN 46285. Tel: 317-276-4491. Fax: 317-277-7839
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Three studies compared olanzapine and haloperidol given orally in maintenance therapy for schizophrenia and related psychoses.

Method

Data were from double-blind extensions of acute studies. The subjects met criteria for schizophrenia, schizophreniform disorder or schizoaffective disorder. Subjects had responded to acute therapy (Brief Psychiatric Rating Scale total score decreased $ 40% from baseline (Studies 1, 2, and 3) or was $ 18 (Studies I and 2)) and were out-patients at their last acute phase visit. Relapse was defined as hospitalisation for psychopathology. Subjects treated with olanzapine in the three studies were pooled to form the olanzapine group and subjects treated with haloperidol were pooled to form the haloperidol group.

Results

Olanzapine-treated subjects experienced less relapse (P=0.034). The Kaplan-Meier estimated one-year risk of relapse was 19.7% with olanzapine and 28% with haloperidol.

Conclusion

Olanzapine was superior to haloperidol in the maintenance therapy of schizophrenia and related psychoses.

Type
Papers
Information
The British Journal of Psychiatry , Volume 172 , Issue 6 , June 1998 , pp. 499 - 505
Copyright
Copyright © 1998 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Declaration of interest

This work was sponsored by Eli Lilly and Company.

References

Beasley, C. M. Jr Sanger, T. Satterlee, W. et al (1996a) Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology, 124, 159–167.CrossRefGoogle ScholarPubMed
Beasley, C. M. Tollefson, G. Jr Tran, P. V. et al (1996b) Olanzapine versus placebo and haloperidol. Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology, 14, 111–123.Google Scholar
Beasley, C. M. Jr Hamilton, S. Crawford, A. M. et al (1997) Olanzapine versus haloperidol: Acute-phase results of the international double-blind olanzapine trial. European Neuropsychopharmacology, 7, 125–137.Google Scholar
Carpenter, W. T. Hanion, T. E. Heinrichs, D. W. et al (1990) Continuous versus targeted medication in schizophrenic out-patients: outcome results. American Journal of Psychiatry, 147, 1138–1148.Google Scholar
Crow, T. J. Macmillan, J. F. Johnson, A. L. et al (1986) A randomised controlled trial of prophylactic neuroleptic treatment. British Journal of Psychiatry, 148, 120–127.CrossRefGoogle ScholarPubMed
Davis, J. M. Kane, J. M. Marder, S. R. et al (1993) Dose response of prophylactic antipsychotics. Journal of Clinical Psychiatry, Suppl. 54. 24–30.Google Scholar
Dellva, M. A. Tran, P. V. Tollefson, G. D. et al (1997) Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. Psychiatric Services, 48, 1571–1577.Google Scholar
Gilbert, P. L. Harris, M. J. McAdams, L. A. et al (1995) Neuroleptic withdrawal in schizophrenic patients. Archives of General Psychiatry, 52, 173–188.Google Scholar
Goldstein, M. J. Rodnick, E. H. Evans, J. R. et al (1978) Drug and family therapy in the aftercare of acute schizophrenics. Archives of General Psychiatry, 35, 1169–1177.Google Scholar
Greenhouse, J. B. & Meyer, M. M. (1991) A note on randomisation and selection bias in maintenance therapy clinical trials. Psychopharmacology Bulletin, 27, 225–229.Google Scholar
Greenhouse, J. B. Stangl, D. Kupfer, D. J. et al (1991) Methodologic issues in maintenance therapy clinical trials. Archives of General Psychiatry, 48, 313–318.Google Scholar
Herz, M. I. Glazer, W. M. Mostert, N. A. et al (1991) Intermittent vs maintenance medication in schizophrenia. Archives of General Psychiatry, 48, 333–339.Google Scholar
Hogarty, G. E. McEvoy, J. P. Munitz, M. et al (1988) Dose of fluphenazine. familial expressed emotion, and outcome in schizophrenia. Archives of General Psychiatry, 45, 797–805.CrossRefGoogle ScholarPubMed
Johnson, D. A. W. Ludlow, J. M. Street, K. et al (1987) Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia. British Journal of Psychiatry, 151, 634–638.Google Scholar
Jolley, A. G. Hirsch, S. R. McRink, A. et al (1989) Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year. British Journal of Psychiatry, 208, 985–990.Google Scholar
Kane, J. M. (1983) Low dose medication strategies in the maintenance treatment of schizophrenia. Schizophrenia Bulletin, 9, 528–532.Google Scholar
Kane, J. M. & Marder, S. R. (1993) Psychopharmacologic treatment of schizophrenia. (Review). Schizophrenia Bulletin, 19, 287–302.Google Scholar
Marder, S. R. Van Putten, T. Mintz, J. et al (1984) Costs and benefits of two doses of fluphenazine. Archives of General Psychiatry, 41, 1025–1029.Google Scholar
Marder, S. R. Van Putten, T. & Mintz, J. (1987) Low- and conventional-dose maintenance therapy with fluphenazine decanoate: Two-year outcome. Archives of General Psychiatry, 44, 513–521.Google Scholar
Overall, J. E. & Gorham, D. R. (1962) The Brief Psychiatric Rating Scale. Psychological Reports, 10, 799–812.Google Scholar
Pietzcker, A. Gaebel, W. & Köpeke, W. (1993) Intermittent versus maintenance neuroleptic long-term treatment in schizophrenia: 2-year results of a German multicenter study. Journal of Psychiatric Research, 27, 321–339.CrossRefGoogle Scholar
SAS Institute Inc (1990) SAS/STAT User's Guide. Cary, NC: SAS Institute Inc. Google Scholar
Tollefson, G. D. Beasley, C. M. Tran, P. V. Jr. et al (1997) Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. American Journal of Psychiatry, 154, 457–465.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.